← All trials
NCT06031012
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2023
- Primary completion
- Aug 31, 2024
- Completion date
- Oct 31, 2024
- First posted
- Sep 11, 2023
- Last posted
- Sep 11, 2023
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Air Force Military Medical University, ChinaLead sponsor
- Air Force Military Medical University, ChinaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.